trending Market Intelligence /marketintelligence/en/news-insights/trending/Od1rNzCig12Y16E63r52mA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Nordic Nanovector raises 242.5M kroner to develop non-Hodgkin lymphoma drug

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Nordic Nanovector raises 242.5M kroner to develop non-Hodgkin lymphoma drug

Nordic Nanovector ASA raised gross proceeds of 242.5 million kroner via a private placement of shares.

The Norway-based biotechnology company, which develops therapies for blood-related cancers, sold 11,023,892 new shares at 22 Norwegian kroner apiece.

Net proceeds from the placement are expected to be used to further the clinical development of Betalutin, an investigational drug for treating recurrent non-Hodgkin lymphoma.

Venture capital fund HealthCap VI LP, the company's largest shareholder, was allocated 454,545 shares under the transaction. Following completion, HealthCap will own a total of 6,165,378 shares, representing 9.32% of the company's issued share capital.

DNB Markets and Jefferies International Ltd. acted as joint global coordinators and joint book runners, with ABG Sundal Collier ASA acting as joint book runner.

As of Oct. 17, US$1 was equivalent to 9.17 Norwegian kroner.